Teva Agrees To $420m Securities Settlement For Alleged Price Fixing
Israeli Firm Denies Wrongdoing; Proposed Settlement Requires Final Approval
Denying any wrongdoing or admission of liability, Teva has agreed to a proposed settlement of $420m with a class of investors following allegations that the firm had concealed the true nature of its increase in profits, which artificially inflated the price of Teva’s securities.
You may also be interested in...
Teva is expecting to have a new CEO by the end of next year, after current leader Kåre Schultz indicated that he was unlikely to renew his contract. The president and chief executive has overseen an eventful and transformative period for the Israeli firm.
Industry's big players report fourth quarter results over the next two weeks. Updates on leadership changes, growth targets and deal plans are among the hot topics.
After being found liable for helping fuel the opioid epidemic in New York last month, Teva used the J.P. Morgan Healthcare Conference to explain how it intends to go about overturning the verdict.